Receptor tyrosine kinase targeted therapies in glioblastoma: a systematic review
Audrey Z. Fu, Oliver D. Mowforth, Renuka Chintapalli, Samuel Brown, Francesca Hardyman, Richard Mair · 2026
Read Receptor tyrosine kinase targeted therapies in glioblastoma: a systematic review by Audrey Z. Fu, Oliver D. Mowforth, Renuka Chintapalli, Samuel Brown, Francesca Hardyman, Richard Mair (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13628515.txt.
Description
Audrey Fu and co-authors review targeted drug trials for glioblastoma in a 2026 paper. Glioblastoma is the most common primary brain cancer in adults, with median survival under fifteen months. One of its three main growth pathways runs through receptor tyrosine kinases, cell-surface switches that many drugs aim to block. Yet no single trial has shown a clear survival gain from blocking them.
The review gathered 135 studies covering over nine thousand patients, most with recurrent tumors. Forty-seven different targeted drugs appeared, led by multi-kinase blockers and drugs aimed at two common switches. Only a small share of studies showed a statistically clear survival benefit, and a few more hinted at one. No therapy earned consistent support. The authors point to better biomarkers and cleaner trial design as the way forward.
Catalog record
| CREATOR | Audrey Z. Fu, Oliver D. Mowforth, Renuka Chintapalli, Samuel Brown, Francesca Hardyman, Richard Mair |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |